PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

CRMP2-binding compound, edonerpic maleate, accelerates motor function recovery from brain damage.

Abstract Brain damage such as stroke is a devastating neurological condition that may severely compromise patient quality of life. No effective medication-mediated intervention to accelerate rehabilitation has been established. We found that a small compound, edonerpic maleate, facilitated experience-driven synaptic glutamate AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic-acid) receptor delivery and resulted in the acceleration of motor function recovery after motor cortex cryoinjury in mice in a training-dependent manner through cortical reorganization. Edonerpic bound to collapsin-response-mediator-protein 2 (CRMP2) and failed to augment recovery in CRMP2-deficient mice. Edonerpic maleate enhanced motor function recovery from internal capsule hemorrhage in nonhuman primates. Thus, edonerpic maleate, a neural plasticity enhancer, could be a clinically potent small compound with which to accelerate rehabilitation after brain damage.
PMID
Related Publications

Amyloid-β₂₅₋₃₅ induces impairment of cognitive function and long-term potentiation through phosphorylation of collapsin response mediator protein 2.

Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator.

CaMKII phosphorylates collapsin response mediator protein 2 and modulates axonal damage during glutamate excitotoxicity.

Long-term effects of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate and 6-nitro-7-sulphamoylbenzo(f)quinoxaline-2,3-dione in the rat basal ganglia: calcification, changes in glutamate receptors and glial reactions.

Conventional protein kinase Cβ-mediated phosphorylation inhibits collapsin response-mediated protein 2 proteolysis and alleviates ischemic injury in cultured cortical neurons and ischemic stroke-induced mice.

Authors

Mayor MeshTerms

Neuroprotection

Keywords
Journal Title science (new york, n.y.)
Publication Year Start




PMID- 29622647
OWN - NLM
STAT- MEDLINE
DCOM- 20180411
LR  - 20180411
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 360
IP  - 6384
DP  - 2018 Apr 6
TI  - CRMP2-binding compound, edonerpic maleate, accelerates motor function recovery
      from brain damage.
PG  - 50-57
LID - 10.1126/science.aao2300 [doi]
AB  - Brain damage such as stroke is a devastating neurological condition that may
      severely compromise patient quality of life. No effective medication-mediated
      intervention to accelerate rehabilitation has been established. We found that a
      small compound, edonerpic maleate, facilitated experience-driven synaptic
      glutamate AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic-acid)
      receptor delivery and resulted in the acceleration of motor function recovery
      after motor cortex cryoinjury in mice in a training-dependent manner through
      cortical reorganization. Edonerpic bound to collapsin-response-mediator-protein 2
      (CRMP2) and failed to augment recovery in CRMP2-deficient mice. Edonerpic maleate
      enhanced motor function recovery from internal capsule hemorrhage in nonhuman
      primates. Thus, edonerpic maleate, a neural plasticity enhancer, could be a
      clinically potent small compound with which to accelerate rehabilitation after
      brain damage.
CI  - Copyright (c) 2018 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works.
FAU - Abe, Hiroki
AU  - Abe H
AUID- ORCID: 0000-0001-7441-6664
AD  - Yokohama City University Graduate School of Medicine, Department of Physiology,
      Yokohama, 236-0004, Japan.
FAU - Jitsuki, Susumu
AU  - Jitsuki S
AUID- ORCID: 0000-0002-0822-4303
AD  - Yokohama City University Graduate School of Medicine, Department of Physiology,
      Yokohama, 236-0004, Japan.
FAU - Nakajima, Waki
AU  - Nakajima W
AUID- ORCID: 0000-0002-2396-3112
AD  - Yokohama City University Graduate School of Medicine, Department of Physiology,
      Yokohama, 236-0004, Japan.
FAU - Murata, Yumi
AU  - Murata Y
AUID- ORCID: 0000-0002-6318-2951
AD  - Human Informatics Research Institute, National Institute of Advanced Industrial
      Science and Technology, Ibaraki, 305-8568, Japan.
FAU - Jitsuki-Takahashi, Aoi
AU  - Jitsuki-Takahashi A
AUID- ORCID: 0000-0002-9331-3844
AD  - Yokohama City University Graduate School of Medicine, Department of Physiology,
      Yokohama, 236-0004, Japan.
FAU - Katsuno, Yuki
AU  - Katsuno Y
AD  - Yokohama City University Graduate School of Medicine, Department of Physiology,
      Yokohama, 236-0004, Japan.
FAU - Tada, Hirobumi
AU  - Tada H
AUID- ORCID: 0000-0002-6098-7826
AD  - Yokohama City University Graduate School of Medicine, Department of Physiology,
      Yokohama, 236-0004, Japan.
FAU - Sano, Akane
AU  - Sano A
AUID- ORCID: 0000-0001-7381-031X
AD  - Yokohama City University Graduate School of Medicine, Department of Physiology,
      Yokohama, 236-0004, Japan.
FAU - Suyama, Kumiko
AU  - Suyama K
AUID- ORCID: 0000-0003-0617-7213
AD  - Yokohama City University Graduate School of Medicine, Department of Physiology,
      Yokohama, 236-0004, Japan.
FAU - Mochizuki, Nobuyuki
AU  - Mochizuki N
AUID- ORCID: 0000-0001-8175-7600
AD  - Yokohama City University Graduate School of Medicine, Department of Physiology,
      Yokohama, 236-0004, Japan.
AD  - Toyama Chemical Co., Tokyo, 160-0023, Japan.
AD  - Fujifilm Corporation, Tokyo, 107-0052, Japan.
FAU - Komori, Takashi
AU  - Komori T
AUID- ORCID: 0000-0003-3778-2993
AD  - Yokohama City University Graduate School of Medicine, Department of Physiology,
      Yokohama, 236-0004, Japan.
AD  - Toyama Chemical Co., Tokyo, 160-0023, Japan.
AD  - Fujifilm Corporation, Tokyo, 107-0052, Japan.
FAU - Masuyama, Hitoshi
AU  - Masuyama H
AUID- ORCID: 0000-0002-3501-6796
AD  - Yokohama City University Graduate School of Medicine, Department of Physiology,
      Yokohama, 236-0004, Japan.
AD  - Toyama Chemical Co., Tokyo, 160-0023, Japan.
AD  - Fujifilm Corporation, Tokyo, 107-0052, Japan.
FAU - Okuda, Tomohiro
AU  - Okuda T
AUID- ORCID: 0000-0002-3844-362X
AD  - Toyama Chemical Co., Tokyo, 160-0023, Japan.
AD  - Fujifilm Corporation, Tokyo, 107-0052, Japan.
FAU - Goshima, Yoshio
AU  - Goshima Y
AUID- ORCID: 0000-0002-1944-7051
AD  - Yokohama City University Graduate School of Medicine, Department of Molecular
      Pharmacology and Neurobiology, Yokohama, 236-0004, Japan.
FAU - Higo, Noriyuki
AU  - Higo N
AUID- ORCID: 0000-0002-3448-1696
AD  - Human Informatics Research Institute, National Institute of Advanced Industrial
      Science and Technology, Ibaraki, 305-8568, Japan.
FAU - Takahashi, Takuya
AU  - Takahashi T
AUID- ORCID: 0000-0001-6523-0622
AD  - Yokohama City University Graduate School of Medicine, Department of Physiology,
      Yokohama, 236-0004, Japan. [email protected]
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 0 (1-(3-(2-(1-benzothiophen-5-yl) ethoxy) propyl)-3-azetidinol maleate)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Maleates)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Receptors, AMPA)
RN  - 0 (Thiophenes)
RN  - 0 (collapsin response mediator protein-2)
SB  - IM
CIN - Science. 2018 Apr 6;360(6384):30-31. PMID: 29622641
MH  - Animals
MH  - Brain Injuries/*drug therapy
MH  - Intercellular Signaling Peptides and Proteins/*metabolism
MH  - Male
MH  - Maleates/*metabolism/*pharmacology/therapeutic use
MH  - Mice
MH  - Mice, Knockout
MH  - Mice, Mutant Strains
MH  - Motor Cortex/*drug effects/injuries/physiopathology
MH  - Nerve Tissue Proteins/*metabolism
MH  - Neuronal Plasticity/drug effects
MH  - *Neuroprotection
MH  - Quality of Life
MH  - Receptors, AMPA/metabolism
MH  - Recovery of Function/*drug effects
MH  - Stroke/complications/drug therapy
MH  - Thiophenes/*metabolism/*pharmacology/therapeutic use
EDAT- 2018/04/07 06:00
MHDA- 2018/04/12 06:00
CRDT- 2018/04/07 06:00
PHST- 2017/06/29 00:00 [received]
PHST- 2018/02/01 00:00 [accepted]
PHST- 2018/04/07 06:00 [entrez]
PHST- 2018/04/07 06:00 [pubmed]
PHST- 2018/04/12 06:00 [medline]
AID - 360/6384/50 [pii]
AID - 10.1126/science.aao2300 [doi]
PST - ppublish
SO  - Science. 2018 Apr 6;360(6384):50-57. doi: 10.1126/science.aao2300.